Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells - A mechanism affecting the human lung microenvironment

Clinical and Experimental Immunology

Volumn 105, Issue 2, 1996, Pages 383-388

  Zambello, R ^a   Trentin, L ^a   Enthammer, C ^a   Cipriani, A ^a   Agostini, C ^a   Semenzato, G ^a   Semenzato, Gianpietro ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

BAL lymphocytes; IL 2; IL 2 receptors; Interferon gamma; LAK cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG BIOPSY; LUNG FIBROBLAST; LUNG LAVAGE; LYMPHOKINE ACTIVATED KILLER CELL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030018813     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-762.x     Document Type: Article

References (35)

1. Rankin JA. Pulmonary immunology. Clin Chest Med 1988; 9:387-93.
2. Agostini C, Semenzato G. Immune response in the lung: basic principles. Lung 1990; 168S:1001-12.
3. Pabst R. Is BALT a major component of the human lung immune system? Immunol Today 1992; 13:119-22.
4. Reynolds HY. State of the art: bronchoalveolar lavage. Am Rev Respir Dis 1987; 135:250-60.
5. Hance AJ, Saltini C, Crystal RG. Does de novo immunoglobulin synthesis occur on the epithelial surface of the human lower respiratory tract? Am Rev Respir Dis 1988; 137:17-24.
6. Agostini C, Chilosi M, Zambello R, Trentin L, Semenzato G. Pulmonary immune cells in health and disease: lymphocytes. Eur Respir J 1993; 6:1378-401.
7. Agostini C, Trentin L, Zambello R, Semenzato G. State of the art. HIV-1 and the lung. Infectivity, pathogenic mechanisms and cellular immune response taking place in the lower respiratory tract. Am Rev Respir Dis 1993; 147:1038-51.
8. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. Cancer Res 1981; 41:4420-8.
9. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T lymphocytes in active sarcoidosis. N Engl J Med 1983; 308:793-800.
10. West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DH, Thurman GB, Oldham RK. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
11. Rosenberg SA, Lotze MT, Mulè JJ. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 1988; 108:853-64.
12. Zambello R, Trenutin L, Feruglio C, Bulian P, Masciarelli M, Cipriani A, Agostini C, Semenzato G. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.Cancer Res 1990; 50:1768-73.
13. Akbar AN, Salmon M, Savill J, Janossy J. A possible role for bcl-2 in regulating T-cell memory - a "balancing act" between cell death and survival. Immunol Today 1993; 14:526-32.
14. Scott S, Pandolfi F, Kurnick J. Fibroblasts mediate T cell survival: a proposed mechanism for retention of primed T cells. J Exp Med 1990; 172:1873-6.
15. Zambello R, Trentin L, Bulian P et al. Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. Blood 1990; 76:2080-5.
16. Wijdenes J, Clement C, Morel-Fourrier B, Beliard R, Hervé P, Peters A. A monoclonal antibody against the human IL-2 receptor with high inhibitory activity on IL-2 induced proliferation of T cells, experimental and clinical results. In: Kaplan JC, Green DR, Bleackly RC, eds. Cellular basis of immune modulation. Progress in leukocyte biology, Vol. 9. New York: Liss, 1989:551-6.
17. Takeshita T, Goto Y, Kada K, Nagata K, Asao H, Sugamura K. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor. J Exp Med 1989; 170:291-301.
18. Ishii N, Takeshita T, Kimura Y, Tada K, Kondo M, Nakamura M, Sugamura K. Expression of the IL-2 receptor γ chain on various populations in human peripheral blood. Int Immunol 1994; 6:1273-7.
19. Zambello R, Trentin L, Bulian P, Cassatella M, Raimondi R, Chisesi T, Agostini C, Semenzato G. Role of tumor necrosis factor (TNF)-α and its specific receptors in patients with lymphoproliferative disease of granular lymphocytes. Blood 1992;80:2030-5.
20. Young IT. Proof without prejudice: use of the Kolmoronov Smirnov test for analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25:935-41.
21. Roth MD, Golub SH. Inhibition of lymphokine-activated killer cells by function by human alveolar macrophages. Cancer Res 1989; 49:4690-5.
22. Bordignon C, Villa F, Allavena P, Introna A, Biondi A, Avallone R, Mantovani A. Inhibition of natural killer activity by human bronchoalveolar lavage macrophages. J Immunol 1982; 129:587-91.
23. Semenzato G, Trentin L, Zambello R, Agostini C, Cipriani A, Marcer G. Different types of cytotoxic lymphocytes recovered from the lungs of patients with hypersensitivity pneumonitis. Am Rev Respir Dis 1988; 137:70-74.
24. Plaisance S, Rubistain E, Alileche A et al. Expression of the interleukin-2 receptor on human fibroblasts and its biological significance. Int Immunol 1992; 4:739-46.
25. Plaisance S, Rubistein E, Alileche A, Benoit P, Jasmin C, Azzarone B. The IL-2 receptor present on human embrionic fibroblasts is functional in the absence of p64/IL-2Rγ chain. Int Immunol 1993; 5:843-8.
26. Schwachula A, Rieman D, Kemlen A, Langner J. Characterization of the immunophenotype, and functional properties of fibroblast-like synoviocytes in comparison to skin fibroblasts and umbelical vein endothelial cells. Immunobiol 1994; 190:67-92.
27. Trinchieri G. Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 1994; 180:417-21.
28. Wiebke EA, Custer MC, Rosenberg SA, Lotze MT. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex restricted effectors reveals differential effects on natural and lumphokine-activated killing. J Biol Response Mod 1990; 9:113-6.
29. Gromberg A, Ferm M, Tsai L, Kiessling R. Interferon is able to reduce susceptibility to human lymphokine activated killer (LAK) cells. Cell Immunol 1989; 118:10-21.
30. Trudel JL, Youngman KR, West GA, Fazio VW, Fiocchi C. Lymphokine-activated killer (LAK) cells from human intestinal mucosa: cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer. J Surg Res 1988; 44:445-4.
31. Hunninghake GW, Hemken C, Brudy M, Monik M. Immune Interferon is a growth factor for human lung fibroblasts. Am Rev Respir Dis 1986; 134:1025-8.
32. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswall P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987; 138:1657-9.
33. Haren Bellan A, Quillet A, Marchiol C, DeMars R, Tursz T, Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci USA 1986; 83:5688-2.
34. + NK and LAK cells. Scan J Immunol 1994; 40:665-8.
35. Ettinghausen SE, Lipford HE, Mulè JJ, Rosenberg SA. Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer (LAK) cells. J Immunol 1985; 135:2623-35.